AdAlta secures key BZDS1901 CAR-T milestones as program advances toward Australian manufacturing and FDA engagement
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression – Optimi Health Corp.
Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial
EchoIQ/Pro Medicus: Binding Heads of Agreement secured with leading health imaging company, Pro Medicus Limited (ASX: PME)
ENA Respiratory Receives USPTO Notice of Allowance for Two Patents Covering TLR2 Agonists and Rhinovirus-Mediated COPD Exacerbations
Oncosil: Peer-reviewed publication demonstrates localised distribution of Oncosil microparticles in pancreatic cancer tissue
Oncosil: TRIPP-FFX Clinical trial meets co-primaryOncosil: TRIPP-FFX Clinical trial meets co-primary endpoints endpoints
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
NeuroScientific Biopharmaceuticals Reports Strong Outcomes in Fistulising Crohn’s Disease Patients Treated Under Special Access Program with StemSmart(TM)